Prosecution Insights
Last updated: October 04, 2026
Application No. 18/707,499

KRAS G12C INHIBITORS

Non-Final OA §112
Filed
May 03, 2024
Priority
Nov 05, 2021 — provisional 63/276,478 +3 more
Examiner
RAHMANI, NILOOFAR
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Frontier Medicines Corporation
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
886 granted / 1143 resolved
+17.5% vs TC avg
Minimal -3% lift
Without
With
+-2.9%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 11m
Avg Prosecution
47 currently pending
Career history
1157
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
13.8%
-26.2% vs TC avg
§102
28.5%
-11.5% vs TC avg
§112
38.4%
-1.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1143 resolved cases

Office Action

§112
DETAILED ACTION Claims 1, 115-129, 133-144, 146-149 are pending in the instant application. 2. Claim Rejections - 35 USC § 112 The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 115-129, 133-144, 146-149 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 1, 115-129, 133-144, 146-149 are rejected because the term “or a salt thereof; and/or an isotopologue thereof;” is confusing. Correction is required. 3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is 571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /NILOOFAR RAHMANI/ Primary Examiner, Art Unit 1691 09/08/2026
Read full office action

Prosecution Timeline

May 03, 2024
Application Filed
Jun 25, 2026
Examiner Interview (Telephonic)
Sep 04, 2026
Request for Continued Examination
Sep 08, 2026
Response after Non-Final Action
Sep 11, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735419
PROCESS FOR RACEMIZING AND ISOLATING ATROPISOMERS OF 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE
3y 5m to grant Granted Sep 15, 2026
Patent 12734153
METHODS FOR AMELIORATING AND PREVENTING AGE-RELATED MUSCLE DEGENERATION
2y 10m to grant Granted Sep 15, 2026
Patent 12729200
GLP-1R Agonist and Therapeutic Method Thereof
1y 1m to grant Granted Sep 08, 2026
Patent 12723052
TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS
2y 11m to grant Granted Sep 01, 2026
Patent 12709616
NEK7 INHIBITORS
2y 10m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
75%
With Interview (-2.9%)
1y 11m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1143 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month